Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.

Revenue
+1.57%
EPS
−75.4%
Free cash flow
+278.7%
Total debt
−14.7%

Quarter to September 2026, against a year earlier

60.89 2.83 +4.87%
Market cap
$8.9B
P/E
0.0×
Fwd P/E
−412×
Dividend yield
0.34%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100

Bruker Corporation 8-K filed Jan 8, 2024

Period ended Jan 8, 2024 · Filed · accepted 12:09 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov